DGAP-News: co.don AG

DGAP-News: co.don Aktiengesellschaft: co.don AG expands Executive Board with appointment of Chief Financial Officer

DGAP-News: co.don Aktiengesellschaft / Key word(s): Change of Personnel co.don Aktiengesellschaft: co.don AG expands Executive Board with appointment of Chief Financial Officer

12.05.2016 / 12:30 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press release

co.don AG expands Executive Board with appointment of Chief Financial Officer

Berlin, 12 May 2016 - The Supervisory Board of co.don AG expanded the Executive Board on 10 May 2016, appointing Mr Ralf M. Jakobs as an Executive Board member.

As the company's Chief Financial Officer (CFO), Mr Jakobs will be responsible for Human Resources and IT in addition to leading the finance function.

Mr Jakobs has many years of international capital market experience, with a focus on corporate finance, risk controlling, risk management and personnel development. He holds a diploma in business law and has extensive national and international management expertise.

The expansion of the Executive Board is another step in the commercialisation of the company; it creates the necessary management structures to lead the planned internationalisation of its business model.

About co.don(R) AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects.co.don condrosphere(R) is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere(R) has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere(R) has been used for more than 10 years in over 120 clinics to treat more than 9,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO) More information is available at www.ihre-zellzuechter.de or www.codon.de

Press contact

Matthias Meißner, M.A. Corporate communications / IR / PR +49 +49 3328 43460 Fax: +49 03328 434643 pr@codon.de

---------------------------------------------------------------------------

12.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: co.don Aktiengesellschaft Warthestraße 21 14513 Teltow Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: info@codon.de Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service ---------------------------------------------------------------------------

463103 12.05.2016